Allogeneic stem cell transplantation for type B insulin resistance

Thomas  Ebert; Gerhard  Behre; Lorenz  Weidhase; Vladan  Vucinic; Cornelia Gewert; Robert K Semple; Michael Stumvoll; Anke Tönjes

doi:10.3389/fmed.2023.1200037

Allogeneic stem cell transplantation for type B insulin resistance

Thomas Ebert, Gerhard Behre, Lorenz Weidhase, Vladan Vucinic, Cornelia Gewert, Robert K Semple, Michael Stumvoll, Anke Tönjes

Research output: Contribution to journal › Article › peer-review

Abstract

Type B insulin resistance (TBIR) is a rare, often fulminant form of insulin resistance caused by
autoantibodies against the insulin receptor. Untreated, its mortality is high. Various
immunosuppressive regimens have shown efficacy, but treatment effects are variable and timedelayed, and drug-induced complications may arise. We report a patient with TBIR arising as a complication of Wiskott–Aldrich syndrome. Stable remission of TBIR was achieved through allogeneic peripheral blood stem cell transplantation (PBSCT) over a follow-up period of more than 1.5 years. We thus demonstrate that PBSCT can be considered a treatment option in TBIR where conventional immunosuppressive therapy is ineffective or contraindicated.

Original language	English
Journal	Frontiers in Medicine
DOIs	https://doi.org/10.3389/fmed.2023.1200037
Publication status	Published - 29 Aug 2023

Access to Document

10.3389/fmed.2023.1200037

Ebert_compiledAccepted author manuscript, 827 KBLicence: Creative Commons: Attribution (CC-BY)
fmed-10-1200037Final published version, 560 KBLicence: Creative Commons: Attribution (CC-BY)

Causes and Consequences of Pathological Adipose Remodelling
Semple, R.
UK-based charities
1/06/18 → 31/05/23
Project: Research

Cite this

@article{7b9bbe9d88894e6193cd70916b50a6b9,

title = "Allogeneic stem cell transplantation for type B insulin resistance",

abstract = "Type B insulin resistance (TBIR) is a rare, often fulminant form of insulin resistance caused byautoantibodies against the insulin receptor. Untreated, its mortality is high. Variousimmunosuppressive regimens have shown efficacy, but treatment effects are variable and timedelayed, and drug-induced complications may arise. We report a patient with TBIR arising as a complication of Wiskott–Aldrich syndrome. Stable remission of TBIR was achieved through allogeneic peripheral blood stem cell transplantation (PBSCT) over a follow-up period of more than 1.5 years. We thus demonstrate that PBSCT can be considered a treatment option in TBIR where conventional immunosuppressive therapy is ineffective or contraindicated.",

author = "Thomas Ebert and Gerhard Behre and Lorenz Weidhase and Vladan Vucinic and Cornelia Gewert and Semple, {Robert K} and Michael Stumvoll and Anke T{\"o}njes",

note = "Funding Information: This study was funded by the German Research Foundation (DFG)—through SFB 1052, project number 209933838, subproject SFB 1052/2, A01 to MS, SFB 1052/3, C06, as well as SPP 1629 TO 718/2-1 to AT. AT and TE were supported by the German Diabetes Association (DDG). TE was supported by a Novo Nordisk postdoctoral fellowship run in partnership with Karolinska Institutet, Stockholm, Sweden, a Karolinska Institutet Research Foundation grant, as well as by the Swedish Kidney Foundation (Njurfonden) and by the Stiftelsen Stig och Gunborg Westman. TE was further funded through the EFSD Mentorship Programme supported by AstraZeneca. RS was funded by the Wellcome Trust (Grant 210752/Z/18/Z). The authors acknowledge support from the Open Access Publishing Fund of Leipzig University supported by the German Research Foundation (DFG) within the program of Open Access Publication Funding. Publisher Copyright: Copyright {\textcopyright} 2023 Ebert, Behre, Weidhase, Vucinic, Gewert, Semple, Stumvoll and T{\"o}njes.",

year = "2023",

month = aug,

day = "29",

doi = "10.3389/fmed.2023.1200037",

language = "English",

journal = "Frontiers in Medicine",

issn = "2296-858X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Allogeneic stem cell transplantation for type B insulin resistance

AU - Ebert, Thomas

AU - Behre, Gerhard

AU - Weidhase, Lorenz

AU - Vucinic, Vladan

AU - Gewert, Cornelia

AU - Semple, Robert K

AU - Stumvoll, Michael

AU - Tönjes, Anke

N1 - Funding Information: This study was funded by the German Research Foundation (DFG)—through SFB 1052, project number 209933838, subproject SFB 1052/2, A01 to MS, SFB 1052/3, C06, as well as SPP 1629 TO 718/2-1 to AT. AT and TE were supported by the German Diabetes Association (DDG). TE was supported by a Novo Nordisk postdoctoral fellowship run in partnership with Karolinska Institutet, Stockholm, Sweden, a Karolinska Institutet Research Foundation grant, as well as by the Swedish Kidney Foundation (Njurfonden) and by the Stiftelsen Stig och Gunborg Westman. TE was further funded through the EFSD Mentorship Programme supported by AstraZeneca. RS was funded by the Wellcome Trust (Grant 210752/Z/18/Z). The authors acknowledge support from the Open Access Publishing Fund of Leipzig University supported by the German Research Foundation (DFG) within the program of Open Access Publication Funding. Publisher Copyright: Copyright © 2023 Ebert, Behre, Weidhase, Vucinic, Gewert, Semple, Stumvoll and Tönjes.

PY - 2023/8/29

Y1 - 2023/8/29

N2 - Type B insulin resistance (TBIR) is a rare, often fulminant form of insulin resistance caused byautoantibodies against the insulin receptor. Untreated, its mortality is high. Variousimmunosuppressive regimens have shown efficacy, but treatment effects are variable and timedelayed, and drug-induced complications may arise. We report a patient with TBIR arising as a complication of Wiskott–Aldrich syndrome. Stable remission of TBIR was achieved through allogeneic peripheral blood stem cell transplantation (PBSCT) over a follow-up period of more than 1.5 years. We thus demonstrate that PBSCT can be considered a treatment option in TBIR where conventional immunosuppressive therapy is ineffective or contraindicated.

AB - Type B insulin resistance (TBIR) is a rare, often fulminant form of insulin resistance caused byautoantibodies against the insulin receptor. Untreated, its mortality is high. Variousimmunosuppressive regimens have shown efficacy, but treatment effects are variable and timedelayed, and drug-induced complications may arise. We report a patient with TBIR arising as a complication of Wiskott–Aldrich syndrome. Stable remission of TBIR was achieved through allogeneic peripheral blood stem cell transplantation (PBSCT) over a follow-up period of more than 1.5 years. We thus demonstrate that PBSCT can be considered a treatment option in TBIR where conventional immunosuppressive therapy is ineffective or contraindicated.

U2 - 10.3389/fmed.2023.1200037

DO - 10.3389/fmed.2023.1200037

M3 - Article

SN - 2296-858X

JO - Frontiers in Medicine

JF - Frontiers in Medicine

ER -

Allogeneic stem cell transplantation for type B insulin resistance

Abstract

Access to Document

Fingerprint

Projects

Causes and Consequences of Pathological Adipose Remodelling

Cite this